Table 3.
Adjusted logistic regression model for non-adherence (medication possession ratio (MPR) < 0.80)*
| Variable† | Adjusted odds ratio (95% confidence interval) |
| Sociodemographic: | |
| Gender, female | 1.03 (0.88 to 1.19) |
| Age | |
| <45 | 2.43 (1.86 to 3.18) |
| 45 to 49 | 1.45 (1.08 to 1.93) |
| 50 to 54 | 1.09 (0.86 to 1.39) |
| 55 to 59 | 0.78 (0.61 to 0.99) |
| 60 to 64 | 0.75 (0.59 to 0.96) |
| 65 to 69 | 0.84 (0.67 to 1.04) |
| 70 to 74 | 0.83 (0.67 to 1.02) |
| 75 + | 1.00 |
| Health status: | |
| Charlson comorbidity score | |
| 0 | 1.46 (1.20 to 1.77) |
| 1 | 1.21 (0.98 to 1.51) |
| 2 | 1.20 (0.94 to 1.53) |
| 3 or more | 1.00 |
| Gout care: | |
| Number of provider visits for gout prior to ULD initiation | |
| 0 | 1.28 (1.05 to 1.55) |
| 1 | 1.09 (0.92 to 1.30) |
| 2 | 1.00 (0.83 to 1.21) |
| 3 or more | 1.00 |
| Use of acute gout meds 1 to 12 months prior to urate-lowering drug initiation | |
| NSAIDs | 1.15 (1.00 to 1.31) |
*A backward elimination method was used retaining all variables considered to be potentially important. Variables with P values < 0.10 remained in the final models. The Hosmer-Lemeshow goodness of fit had a P value of 0.70; †model after controlling for health plan.
NSAID, non-steroidal anti-inflammatory drug; ULD, urate-lowering drug.